http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018076351-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3a48f9c764182f11efb37ec6f33ee24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2017-12-21^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d8e55efd9259af28537fad4ce665782 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfc2e998d858c1c320393127c18e0df1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a43160774e9459b0a31f10ae8a10c7 |
| publicationDate | 2018-05-17^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018076351-A |
| titleOfInvention | Methods for treating homozygous familial hypercholesterolemia |
| abstract | A method for treating homozygous familial hypercholesterolemia is provided. An antibody (anti-PCSK9 antibody) against a proprotein convertase subtilisin / kexin type 9 (PCSK9), comprising a light chain containing a specific amino acid sequence and a heavy chain containing a specific amino acid sequence, is homozygous. A dosage of about 120 mg to about 3000 mg is administered to a patient diagnosed with sex familial hypercholesterolemia. The anti-PCSK9 antibody is (1) once a week, (2) once every two weeks, (3) once a month, (4) once every three months, (5) once every six months. And (6) administering to the patient on a schedule selected from the group consisting of once every 12 months. [Selection figure] None |
| priorityDate | 2017-12-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 706 of 706.